Full text

Turn on search term navigation

© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes a systemic infection that affects the central nervous system. However, its high infectivity makes comprehensive research with the active virus challenging. Here, we use virus-like particles (VLPs) to explore how exposure to SARS-CoV-2 proteins affects brain activity patterns in wild-type mice and in mice that express the human tau protein. VLP exposure elicits changes in corticosterone and distinct chemokine levels. Longitudinal two-photon microscopy recordings in primary somatosensory and motor cortices reveal substantial short-term increases in cortical activity in VLP-injected mice, with increased stimulus-evoked activity in both genotypes and elevated spontaneous activity in the human tau genotype only. Vehicle-injected human tau mice also show increases in cortical activity patterns. Over the following weeks, activity metrics partially subside but do not completely return to baseline levels. Overall, our data suggest that exposure to SARS-CoV-2 VLPs leads to strong short-term disruption of cortical activity patterns in mice with long-term residual effects. Middle-aged human tau mice, which have a more vulnerable genetic background and overexpression of the tau protein, exhibit more severe pathobiology and may be at risk for more adverse outcomes.

Longitudinal monitoring of the effects of exposure to COVID-19 virus-like proteins on mouse brain reveals alterations of spontaneous and sensory-stimulated activity patterns with increased vulnerability of mice that express the human tau protein.

Details

Title
Exposure to COVID-19 virus-like particles modulates firing patterns of cortical neurons in the mouse brain
Author
Das, Aniruddha 1 ; Icardi, Jacob 1 ; Borovicka, Julie 1 ; Holden, Sarah 2 ; Harrison, Henry F. 3 ; Hirsch, Alec J. 3   VIAFID ORCID Logo  ; Raber, Jacob 4   VIAFID ORCID Logo  ; Dana, Hod 5   VIAFID ORCID Logo 

 Cleveland Clinic Foundation, Department of Neurosciences, Lerner Research Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725) 
 Oregon Health & Science University, Department of Behavioral Neuroscience, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Oregon Health & Science University, Vaccine and Gene Therapy Institute, Beaverton, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Oregon Health & Science University, Department of Behavioral Neuroscience, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Oregon Health & Science University, Departments of Neurology and Radiation Medicine, Division of Neuroscience, ONPRC, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Cleveland Clinic Foundation, Department of Neurosciences, Lerner Research Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Case Western Reserve University, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847) 
Pages
993
Publication year
2025
Publication date
2025
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3226852405
Copyright
© The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.